Clinical Relevance of GB Virus C & Hepatitis C Virus in HIV+ Women

GB 病毒 C 的临床相关性

基本信息

  • 批准号:
    7755157
  • 负责人:
  • 金额:
    $ 23.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-02 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): (GBV-C) is a single-stranded RNA virus that is the closest known relative of hepatitis C virus (HCV). GBV-C has not been associated with any human disease to date. However, several studies have reported a beneficial effect of GBV-C viremia on HIV disease progression - reduced HIV RNA levels, increased CD4 cell counts, and slower disease progression - predominantly in cohorts with a high proportion of men. However, the prevalence of GBV-C differs significantly between men and women, and no large prospective studies have examined the effects of GBV-C co-infection on HIV disease progression in women. In a preliminary study, we found that GBV-C genotype 2 was associated with higher CD4 cell counts compared to genotype 1, and that GBV-C genotype 2 was more sensitive to clearance after interferon treatment than GBV-C genotype 1. Therefore, we propose to evaluate the presence of GBV-C co-infection and the role of GBV-C genotype in modulating HIV disease progression in a well-characterized cohort of women with HIV/AIDS to enhance our knowledge of GBV-C/HIV interactions. This work is significant and innovative because no large prospective studies of the role of GBV-C co-infection in modulating HIV disease have been reported in HIV positive women and because its addresses a potentially beneficial interaction between GBV-C and HIV that could be exploited in the future to develop novel therapeutic strategies. PUBLIC HEALTH RELEVANCE: To date, GB virus type C (GBV-C) has not been associated with any human disease, although several studies have reported a beneficial effect of GBV-C infection on HIV disease progression. The prevalence of GBV-C may differ by gender; however, the adventitious role of GBV-C co-infection on HIV disease, as well as the potential modulatory effects of GBV-C genotype, has not yet been evaluated in a longitudinal manner in women. Such studies could ultimately lead to novel therapeutic strategies to treat HIV disease, particularly among difficult-to-treat populations and/or individuals with limited access to antiretroviral therapy.
描述(由申请人提供):(GBV-C)是一种单链RNA病毒,是已知的与丙型肝炎病毒(HCV)最近的近亲。迄今为止,GBV-C尚未与任何人类疾病相关。然而,一些研究报告了GBV-C病毒血症对HIV疾病进展的有益影响——降低HIV RNA水平,增加CD4细胞计数,减缓疾病进展——主要是在男性比例较高的队列中。然而,GBV-C的患病率在男性和女性之间存在显著差异,并且没有大型前瞻性研究调查GBV-C合并感染对女性艾滋病毒疾病进展的影响。在初步研究中,我们发现GBV-C基因2型与基因1型相比,CD4细胞计数更高,并且GBV-C基因2型比GBV-C基因1型对干扰素治疗后的清除更敏感。因此,我们建议在一个特征明确的HIV/AIDS女性队列中评估GBV-C合并感染的存在以及GBV-C基因型在调节HIV疾病进展中的作用,以增强我们对GBV-C/HIV相互作用的了解。这项工作具有重大意义和创新性,因为在艾滋病毒阳性妇女中没有关于GBV-C联合感染在调节艾滋病毒疾病中的作用的大型前瞻性研究,而且因为它解决了GBV-C和艾滋病毒之间潜在的有益相互作用,可以在未来开发新的治疗策略。公共卫生相关性:迄今为止,GB病毒C型(GBV-C)尚未与任何人类疾病相关,尽管有几项研究报道了GBV-C感染对HIV疾病进展的有益影响。GBV-C的患病率可能因性别而异;然而,GBV-C合并感染对HIV疾病的非确定作用,以及GBV-C基因型的潜在调节作用,尚未在女性中以纵向方式进行评估。这些研究最终可能导致新的治疗策略来治疗艾滋病毒疾病,特别是在难以治疗的人群和/或获得抗逆转录病毒治疗机会有限的个人中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JASON T BLACKARD其他文献

JASON T BLACKARD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JASON T BLACKARD', 18)}}的其他基金

Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
酒精或酒精/合成阿片类药物组合改变 HIV 药物代谢的治疗和机制意义
  • 批准号:
    10542286
  • 财政年份:
    2022
  • 资助金额:
    $ 23.55万
  • 项目类别:
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
酒精或酒精/合成阿片类药物组合改变 HIV 药物代谢的治疗和机制意义
  • 批准号:
    10700069
  • 财政年份:
    2022
  • 资助金额:
    $ 23.55万
  • 项目类别:
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis
BK 多瘤病毒相关出血性膀胱炎的病毒和宿主预测因子
  • 批准号:
    10203959
  • 财政年份:
    2020
  • 资助金额:
    $ 23.55万
  • 项目类别:
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis
BK 多瘤病毒相关出血性膀胱炎的病毒和宿主预测因子
  • 批准号:
    10434701
  • 财政年份:
    2020
  • 资助金额:
    $ 23.55万
  • 项目类别:
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis
BK 多瘤病毒相关出血性膀胱炎的病毒和宿主预测因子
  • 批准号:
    10653831
  • 财政年份:
    2020
  • 资助金额:
    $ 23.55万
  • 项目类别:
Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis
BK 多瘤病毒相关出血性膀胱炎的病毒和宿主预测因子
  • 批准号:
    10029242
  • 财政年份:
    2020
  • 资助金额:
    $ 23.55万
  • 项目类别:
Omics analysis of HIV during synthetic opioid exposure
合成阿片类药物暴露期间 HIV 的组学分析
  • 批准号:
    10548205
  • 财政年份:
    2019
  • 资助金额:
    $ 23.55万
  • 项目类别:
Omics analysis of HIV during synthetic opioid exposure
合成阿片类药物暴露期间 HIV 的组学分析
  • 批准号:
    9883771
  • 财政年份:
    2019
  • 资助金额:
    $ 23.55万
  • 项目类别:
Omics analysis of HIV during synthetic opioid exposure
合成阿片类药物暴露期间 HIV 的组学分析
  • 批准号:
    10158901
  • 财政年份:
    2019
  • 资助金额:
    $ 23.55万
  • 项目类别:
Genotypic& phenotypic characterization of the HCV polymerase (NS5B) in HIV
基因型
  • 批准号:
    9267990
  • 财政年份:
    2013
  • 资助金额:
    $ 23.55万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 23.55万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 23.55万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 23.55万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 23.55万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 23.55万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 23.55万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 23.55万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 23.55万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 23.55万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 23.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了